(Q44729076)

5 December 2017

title

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate (English)

1 reference

5 December 2017

1 reference

1 reference

9

Ehninger G

1 reference

5 December 2017

3

Platzbecker U

1 reference

5 December 2017

Illmer T

1

1 reference

5 December 2017

Schaich M

2

1 reference

5 December 2017

Freiberg-Richter J

4

1 reference

5 December 2017

Oelschlägel U

5

1 reference

5 December 2017

von Bonin M

6

1 reference

5 December 2017

Pursche S

7

1 reference

5 December 2017

Bergemann T

8

1 reference

5 December 2017

Schleyer E

10

1 reference

5 December 2017

publication date

1 March 2004

1 reference

5 December 2017

1 reference

5 December 2017

volume

18

1 reference

5 December 2017

issue

3

1 reference

5 December 2017

page(s)

401-408

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403257

5 December 2017

exact match

0 references

cites work

STI-571 in chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

Multidrug resistance in cancer: role of ATP-dependent transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

Gene rearrangement: a novel mechanism for MDR-1 gene activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403257

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2403257

1 reference

5 December 2017

1 reference